Shionogi & Co Ltd ADR (SGIOY PINK) stock market data APIs
$8.9687
-0.03(-0.3%)
as of September 15, 2025
Try our APIs with
free plan!
Shionogi & Co Ltd ADR Financial Data Overview
Price chart is built with
Anychart
Shionogi & Co., Ltd. researches, develops, manufactures, and distributes pharmaceuticals, diagnostic reagents, and medical devices. It offers and develops drugs in the areas of infectious diseases, COVID-19, tumors, sclerosis, pomp, fragile X syndrome, and other diseases. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.
Prev. Close
8.9687
Open
8.9345
High
9.0255
Low
8.9256
52 wk Range
6.5205-9.193
Market Cap
15 317 M
P/E Ratio
13.1618
Shares Outstanding
1 702 M
Revenue
440 495 M
EPS
0.16
Dividends (Yield)
0.0232
Beta
0.138
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Shionogi & Co Ltd ADR (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Shionogi & Co Ltd ADR data using free add-ons & libraries
Get Shionogi & Co Ltd ADR Fundamental Data
Shionogi & Co Ltd ADR Fundamental data includes:
- Net Revenue: 440 495 M
- EBITDA: 184 653 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-07-28
- EPS/Forecast: 0.1388
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Shionogi & Co Ltd ADR News
New
Bioversys Reports Corporate Highlights and Key Financials For the First Half 2025
BioVersys BV100: successful end of Phase 2 meeting with US FDA following Positive Phase 2 read-out in Ventilator-Associated Bacterial Pneumonia (VABP); Phase 3 on track to initiate in 2025; Formulati...
Can Shionogi’s Rally Continue After Key Drug Approval in 2025?
If you are on the fence about whether to buy, sell, or hold Shionogi stock, you are definitely not alone. Investors have been keeping a close eye on Shionogi’s price swings, wondering if there is mo...
Shionogi to Present New Data from Anti-Infective Portfolio at IDWeek
Scientific Contributions at Congress Include Real-World Evidence on More Than 1,000 Cefiderocol Patients Findings from Antimicrobial Surveillance Program Will be Featured in Oral and Poster Presentat...
FDA Accepts Shionogi’s Ensitrelvir NDA as the First Oral Therapy for the Prevention of COVID-19 Following Exposure
Application is based on results from SCORPIO-PEP, the first and only Phase 3 study of an oral antiviral to meet the primary endpoint of preventing COVID-19 following exposure to an infected individual...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
